LOGIN  |  REGISTER
C4 Therapeutics

R1 RCM to Present at Upcoming Investor Conferences

July 31, 2023 | Last Trade: US$14.31 0.00 0.00

MURRAY, Utah, July 31, 2023 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ: RCM), a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers, today announced its management team will present at two upcoming conferences:

  • The 2023 KeyBanc Technology Leadership Forum on Tuesday, August 8 at 1:00pm ET
  • The 2023 Baird Global Healthcare Conference on Tuesday, September 12 at 3:10pm ET

A live audio webcast of each presentation will be available on the Investor Relations section of R1’s website at r1rcm.com. A replay of the webcast will be available for 90 days following the live webcast.

About R1 RCM

R1 is a leading provider of technology-driven solutions that transform the patient experience and financial performance of hospitals, health systems, and medical groups. R1’s proven and scalable operating models seamlessly complement a healthcare organization’s infrastructure, quickly driving sustainable improvements to net patient revenue and cash flows while reducing operating costs and enhancing the patient experience. To learn more, visit: www.r1rcm.com.

Contact:
R1 RCM Inc.
Investor Relations:
Atif Rahim
312.324.5476
This email address is being protected from spambots. You need JavaScript enabled to view it.

Media Relations:
Allison + Partners
Amanda Critelli
This email address is being protected from spambots. You need JavaScript enabled to view it.

Stock Quote

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page